Developed Formulas
  • Supports a balanced intestinal microbiome

  • Reduces infant colic and crying time

  • Antimicrobial & anti inflammatory activity

  • Improves stool consistency

  • Reduces vomiting

Ready to market
Clinical test
In vitro test
Allergen Free
Real time stability
Strain in oil

Bifidobacterium breve BR03 (DSM 16604)
Bifidobacterium breve B632 (DSM 24706)

Label Claim

Food supplement with probiotic strains.

Effective nutraceutical combination
Scientific Rationale

Infantile colic is a frequent condition in newborns during the first three months post-birth, affecting 10% to 30% of infants. It is typified by prolonged and uncontrollable crying episodes that exceed three hours per day, for more than three days per week. Notably, colicky infants often exhibit slower development, lower stability and alpha diversity in their intestinal microbiota, an imbalance in its composition with reduced levels of Bifidobacteria and Lactobacilli, a predominance of gram-negative bacteria (especially coliforms), and increased intestinal inflammation.

BIFIBABY® contains two Bifidobacterium strains chosen for their supportive properties:

  • Colonization: These strains are capable of colonizing the intestinal microflora in children and reducing total fecal coliforms [1-3].

  • Anti-pathogenic activities: They exhibit significant antimicrobial activity against gas-producing coliforms isolated in colicky infants and various strains of E. coli, including the pathogenic O157:H7 strain [4,7].

  • Anti-inflammatory activity: The strains in BIFIBABY® modulate the immune system by exerting anti-inflammatory effects [6].

BIFIBABY® has been the subject of extensive research for its positive effects on gut health in babies and children, including numerous in vitro studies on the strains and three different clinical studies on infants. These in vitro studies have demonstrated the strains’ remarkable anti-inflammatory and antimicrobial properties against various E. coli strains and Enterobacteriaceae from colicky infants [4,7].

  • In the first clinical study, administering BIFIBABY® to healthy children for 21 days proved effective in colonizing the gut and decreasing total fecal coliforms [3].

  • The second study showed that supplementation with BIFIBABY® to both breast-fed and bottle-fed infants for 90 days effectively reduced the duration of daily crying [1].

  • In the final clinical study, BIFIBABY® treatment in breast-fed and bottle-fed infants over 90 days helped prevent gastrointestinal disorders. It reduced the frequency of daily vomiting and bowel movements and improved stool consistency [2].


1. Giglione E. et al. The Association of Bifidobacterium breve BR03 and B632 is Effective to Prevent Colics in Bottle-fed Infants: A Pilot, Controlled, Randomized, and Double-Blind Study. J Clin Gastroenterol. 2016;50 Suppl 2, Proceedings from the 8th Probiotics, Prebiotics & New Foods for Microbiota and Human Health meeting held in Rome, Italy on September 13-15, 2015:S164-S167. doi:10.1097/MCG.0000000000000693

2. Aloisio I. et al. Three-Month Feeding Integration With Bifidobacterium Strains Prevents Gastrointestinal Symptoms in Healthy Newborns. Front Nutr. 2018 May 25;5:39. doi: 10.3389/fnut.2018.00039.

3. Mogna L. et al. Capability of the two microorganisms Bifidobacterium breve B632 and Bifidobacterium breve BR03 to colonize the intestinal microbiota of children. J Clin Gastroenterol. 2014;48 Suppl 1:S37-S39. doi:10.1097/MCG.0000000000000234 

4. Simone M. et al. The probiotic Bifidobacterium breve B632 inhibited the growth of Enterobacteriaceae within colicky infant microbiota cultures. Biomed Res Int. 2014;2014:301053. doi: 10.1155/2014/301053.

5. Aloisio I. et al. Characterization of Bifidobacterium spp. strains for the treatment of enteric disorders in newborns. Appl Microbiol Biotechnol 2012, 96:1561–1576. Doi: 10.1007/s00253-012-4138-5

6. Nicola S. et al. Interaction between probiotics and human immune cells: the prospective anti-inflammatory activity of Bifidobacterium breve BR03. AgroFOOD, 2010; 21(2):S44-47.

7. Mogna L. et al. Assessment of the in vitro inhibitory activity of specific probiotic bacteria against different Escherichia coli strains. J Clin Gastroenterol. 2012; 46 Suppl:S29-32